Rallybio Raises $37M in Series A Financing

Rallybio, LLC, a Farmington, Conn.-based biotechnology company established to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders, secured $37.0m in Series A funding.

The round was led by 5AM Ventures, Canaan Partners, and New Leaf Venture Partners with additional public-sector participation from Connecticut Innovations.

Co-founded in 2018 by Jeffrey Fryer, CPA, Martin Mackay, PhD, and Stephen Uden, MD (left to right), Rallybio will develop innovative drug candidates against mechanisms that have biological rationales focusing on antibodies, small molecules and engineered proteins.

The company is based at the University of Connecticut’s Technology Incubation Program (in Farmington, CT).



Join the discussion